权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Role of Diabetes in MERS Coronavirus Pathogenesis

糖尿病在 MERS 冠状病毒发病机制中的作用

基本信息

批准号：
10196973
负责人：
Matthew Bryan Frieman
金额：
$ 55.69万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-16 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10196973
关键词：
Alveolar Alveolar Cell Animal Model Antiviral Agents Antiviral Therapy Architecture Carbohydrates Case Fatality Rates Case Study Cell surface Cells Cessation of life Clinical Complex Mixtures Coronavirus Coronavirus Infections Data Diabetes Mellitus Diabetic mouse Diet Disease Disease Outbreaks Disease Outcome Effectiveness Exhibits Future Glare Goals Health Personnel Heart Diseases High Fat Diet Human Immune Immune response Immunosuppression Infection Inflammatory Innate Immune Response Kidney Failure Kinetics Knowledge Lead Link Lung Lung Inflammation Lung diseases Middle East Respiratory Syndrome Middle East Respiratory Syndrome Coronavirus Modeling Monoclonal Antibodies Morbidity - disease rate Mucous Membrane Mucous body substance Mus Non-Insulin-Dependent Diabetes Mellitus Pathogenesis Pathogenicity Pathway interactions Patients Persons Poly I-C Predisposition Production Proteins Public Health Respiratory System Risk Role Saudi Arabia South Korea Structure Surface Therapeutic Time Treatment Efficacy Vaccines Virion Virus Virus Diseases Work anti-viral efficacy chemokine comorbidity comparative cytokine diabetic diabetic patient effective therapy experimental study in vivo influenza virus vaccine microbial mortality mouse model novel pathogen permissiveness receptor respiratory infection virus respiratory virus response targeted treatment therapeutically effective

项目摘要

Project summary: Here we seek to identify the role of diabetes in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) pathogenesis. MERS-CoV emerged in 2012 in Saudi Arabia leading to over 2200 infections with a ~35% case fatality rate. The majority of lethal MERS-CoV infections are associated with a comorbidity, with diabetes as the top comorbidity. We have found that MERS-CoV pathogenesis is exacerbated in a mouse with pre-existing diabetes. We will determine the mechanism for this enhanced disease by determining the role of the changes in lung architecture, and immune response. In Aim1 we will determine whether accessibility of the Type 2 alveolar cells, the target cells for MERS-CoV in the alveoli, is increased in diabetic mice compared to normal mice. Our data suggests that at the earliest points of infection, the alveoli are highly susceptible to MERS- CoV but normal mouse Type 2 alveolar cells are not. We will evaluate the mucus and architecture of the lungs to determine if there is a difference that could explain the differential infection. In Aim 2, we will determine if the immune response in diabetic mice is different than normal mice. A difference in the immune response, especially innate immune response, could explain the susceptibility differences in diabetic and normal mice. In Aim 3 we will determine whether therapeutics that are effective in normal mice are deficient in diabetic mice with the goal of altering those therapeutics in the future for more effective therapies for comorbid patients. Together this proposal will determine why diabetic mice and potentially humans are highly susceptible to MERS-CoV.

项目总结: